Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D 1 , D 2 and D 3 receptors

Author： Perachon S.   Schwartz J.-C.   Sokoloff P.  

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.366, Iss.2, 1999-02, pp. : 293-300

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dual Ligands Targeting Dopamine D2 and Serotonin 5-HT1A Receptors as New Antipsychotical or Anti-Parkinsonian Agents

By  

Current Medicinal Chemistry, Vol. 21, Iss. 4, 2014-02 ,pp. : 437-457

Bentham Science Publishers

Access to resources Recommend Favorite

Relative affinities of dopaminergic drugs at dopamine D 2 and D 3 receptors

By Levant B.   Grigoriadis D.E.   De Souza E.B.  

European Journal of Pharmacology, Vol. 278, Iss. 3, 1995-05 ,pp. : 243-247

Elsevier

Access to resources Recommend Favorite

The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors

By Wicke K.   Garcia-Ladona J.  

European Journal of Pharmacology, Vol. 424, Iss. 2, 2001-07 ,pp. : 85-90

Elsevier

Access to resources Recommend Favorite

Modification of dopamine D 1 receptor knockout phenotype in mice lacking both dopamine D 1 and D 3 receptors

By Karasinska J.M.   George S.R.   El-Ghundi M.   Fletcher P.J.   O'Dowd B.F.  

European Journal of Pharmacology, Vol. 399, Iss. 2, 2000-07 ,pp. : 171-181

Elsevier

Access to resources Recommend Favorite

Functional and pharmacological distinctions between subtypes of dopamine D-2 receptors

By Spano P.F.   Memo M.   Missale C.   Pizzi M.   Sigala S.   Valerio A.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 181-182

Elsevier

Access to resources Recommend Favorite